Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

350.15 -3.80 (-1.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,391,832
Open 354.00
Bid (Size) 348.80 (1)
Ask (Size) 350.80 (1)
Prev. Close 353.95
Today's Range 348.46 - 354.35
52wk Range 282.21 - 387.42
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
Exposures Product Safety
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review
Treasury yields and crude oil came off multimonth lows on Friday's jobs report. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence Fossil Fuels

Performance

YTD
+22.42%
+22.42%
1 Month
-7.43%
-7.43%
3 Month
+1.80%
+1.80%
6 Month
+5.28%
+5.28%
1 Year
+10.26%
+10.26%

More News

Read More
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing Treatment
Via Investor's Business Daily
Exposures Product Safety
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
Via The Motley Fool
Healthcare Gems: 3 Essential Long-Term Stock Picks
Via InvestorPlace
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
Via The Motley Fool
5 Unstoppable Trends to Invest $1,000 in for 2024
Via The Motley Fool
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
Via InvestorPlace
Vertex Appoints Nancy Thornberry to its Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Better Growth Stock: CRISPR Therapeutics vs. Invitae
Via The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Via The Motley Fool
A Bull Market Is Coming. Here Are 3 Stocks You'll Absolutely Want to Own.
Via The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
Via The Motley Fool
5 Top Stocks to Buy Before 2024
Via The Motley Fool
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist
Via The Motley Fool
3 Biotech Stocks That Could Be Multibaggers in the Making
Via InvestorPlace
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
Via InvestorPlace
Biotech And Healthcare Portfolio Playbook For December 2023/24
Via Talk Markets
5 Stocks You Can Confidently Invest $500 In Right Now
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.